Successful treatment with botulinum toxin A after failed augmentation ileocystoplasty

Nature Clinical Practice Urology

Volumn 4, Issue 5, 2007, Pages 280-284

  Apostolidis, Apostolos ^a,c   Popat, Roshni ^b   Harper, Matthew ^b   Fowler, Clare J ^b   Dasgupta, Prokar ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN;

ADULT; ARTICLE; BACTERIAL INFECTION; BLADDER CATHETERIZATION; BLADDER RECONSTRUCTION; CASE REPORT; CYSTOMETRY; CYSTOSCOPE; DETRUSOR DYSSYNERGIA; DISEASE SEVERITY; FOLLOW UP; HUMAN; ILEOCYSTOPLASTY; INFORMED CONSENT; INJECTION SITE DISCOMFORT; LOCAL ANESTHESIA; LOWER URINARY TRACT SYMPTOM; MALE; MYELITIS; OUTPATIENT CARE; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; SALVAGE THERAPY; SURGICAL TECHNIQUE; TREATMENT FAILURE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; URODYNAMICS;

ADMINISTRATION, INTRAVESICAL; ANASTOMOSIS, SURGICAL; BOTULINUM TOXIN TYPE A; CYSTOSCOPY; FOLLOW-UP STUDIES; HUMANS; ILEUM; MALE; MIDDLE AGED; RETREATMENT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINARY DIVERSION; URODYNAMICS;

EID: 34248590954     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0799     Document Type: Article

References (18)

1. Uebersax JS et al. (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: The Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14: 131-139
2. Popat R et al. (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174: 984-988
3. Jensen MP et al. (1998) Assessment of pain during medical procedures: A comparison of three scales. Clin J Pain 14: 343-349
4. Hampel C et al. (2003) Epidemiology and etiology of overactive bladder [German]. Urologe A 42: 776-786
5. Abrams P et al. (2002) The standardization of terminology of lower urinary tract function: Report from the Standardization Subcommittee of the Internatlonal Continence Society. Neurourol Urodyn 21: 167-178
6. Chartier-Castler E et al. (2005) Neurologic urinary and fecal incontinence. In Incontinence 1059-1162 (eds Abrams P et al. Paris: Health Publications Ltd
7. de Groat WC et al. (1990) Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 30 (Suppl): S71-S77
8. Greenwell TJ et al. (2001) Augmentation cystoplasty. BJU Int 88: 511-525
9. Andersson KE and Yoshida M (2003) Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur Urol 43 1-5
10. de Seze M et al. (1999) Intravesical instillation of capsaicin in urology: A review of the literature. Eur Urol 36: 267-277
11. Silva C et al. (2000) Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: Long-term results for the treatment of detrusor hyperreflexia. Eur Urol 38: 444-452
12. Dasgupta P et al. (2000) The effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyper-reflexia. BJU Int 85: 238-245
13. Brady C et al. (2004) P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin (RTX). Eur Urol 46: 247-253
14. Reitz A et al. (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510-515
15. Grosse J et al. (2005) Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 147: 653-659
16. Schurch B et al. (2005) Botulinum to)dn type A is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174: 196-200
17. Apostolidis A et al. (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49: 644-650
18. De Laet K and Wyndaele JJ (2005) Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 43: 397-399